annb0t
Top 20
Wall Street's concerns about GLP-1s' impact on medical device makers and other sectors were back in full swing after glucose monitoring device seller Dexcom (DXCM) slashed its full-year guidance after an earnings miss last week.
However, Dexcom's troubles appear unrelated to the weight loss and diabetes drug frenzy, as competitors such as Abbott (ABT) and Medtronic (MDT) haven't been pressured by the miss, once again allaying Wall Street's fears.
The company attributed its guidance to a fumble...
>>> Read more: Wall Street is still jittery on GLP-1s
However, Dexcom's troubles appear unrelated to the weight loss and diabetes drug frenzy, as competitors such as Abbott (ABT) and Medtronic (MDT) haven't been pressured by the miss, once again allaying Wall Street's fears.
The company attributed its guidance to a fumble...
>>> Read more: Wall Street is still jittery on GLP-1s
